60.2
Amy Stoll-D’Astice
Pancreatic Cancer Action Network
Amy Stoll-D’Astice has made significant contributions to oncology research through several studies on metastatic pancreatic cancer. In Phase 1b study Pancan-SR1, a combination of gemcitabine, nab-paclitaxel, canakinumab, and spartalizumab targeting IL-1β and PD-1 showed initial efficacy in treating the disease. This work has relevance for patients with refractory metastatic pancreatic adenocarcinoma, particularly those with high hyaluronan levels. Additionally, research on albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment has expanded understanding of advanced pancreatic cancer treatment options. The IASLC Lung Cancer Staging Project has also provided insights into resection margin status and proposed residual tumor descriptors for non-small cell lung cancer, offering valuable contributions to the field.